Sagimet Biosciences Inc. financial data

Symbol
SGMT on Nasdaq
Location
155 Bovet Rd., Suite 303, San Mateo, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
3-V Biosciences, Inc. (to 2/25/2019)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 3.72 %
Return On Equity -20.8 % -241%
Return On Assets -20.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.7M shares
Common Stock, Shares, Outstanding 0 shares -100%
Weighted Average Number of Shares Outstanding, Basic 31.9M shares +16739%
Weighted Average Number of Shares Outstanding, Diluted 31.9M shares +16739%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2M USD
Research and Development Expense 22.2M USD +35%
General and Administrative Expense 16.1M USD +79.6%
Operating Income (Loss) -36.3M USD -50.1%
Net Income (Loss) Attributable to Parent -29.3M USD -4.34%
Earnings Per Share, Basic -0.25 USD/shares +99.3%
Earnings Per Share, Diluted -0.25 USD/shares +99.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 96M USD +418%
Marketable Securities, Current 70.4M USD
Cash, Cash Equivalents, and Short-term Investments 189M USD +919%
Other Assets, Current 130K USD +21.5%
Assets, Current 167M USD +681%
Operating Lease, Right-of-Use Asset 151K USD +4.86%
Assets 189M USD +779%
Accounts Payable, Current 1.99M USD -26.8%
Employee-related Liabilities, Current 657K USD +271%
Accrued Liabilities, Current 3.58M USD
Liabilities, Current 5.65M USD +7.1%
Liabilities 5.73M USD +8.24%
Accumulated Other Comprehensive Income (Loss), Net of Tax -23K USD
Retained Earnings (Accumulated Deficit) -264M USD -12.4%
Stockholders' Equity Attributable to Parent 183M USD
Liabilities and Equity 189M USD +779%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.21M USD +12.4%
Net Cash Provided by (Used in) Financing Activities 105M USD
Net Cash Provided by (Used in) Investing Activities 3M USD -84.5%
Common Stock, Shares Authorized 0 shares -100%
Common Stock, Shares, Issued 0 shares -100%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 75.1M USD +47456%
Deferred Tax Assets, Valuation Allowance 55.1M USD +15.2%
Deferred Tax Assets, Gross 55.2M USD +15.2%
Operating Lease, Liability 65K USD -69.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -29.3M USD -20.3%
Lessee, Operating Lease, Liability, to be Paid 66K USD -72.2%
Operating Lease, Liability, Current 153K USD +9.29%
Lessee, Operating Lease, Liability, to be Paid, Year One 66K USD -58%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1K USD -96.2%
Deferred Tax Assets, Operating Loss Carryforwards 31.1M USD +8.33%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 1.78M USD +16.3%
Additional Paid in Capital 448M USD +1116%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 43K USD -4.44%
Share-based Payment Arrangement, Expense 5.37M USD +37.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares